Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis - Takeaways - MDSpire

Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis

  • By

  • Ejike Daniel Eze

  • Leopold Ntakirutimana

  • Swase Dominic Terkimbi

  • Muluken Walle

  • Abdullahi Hussein Umar

  • Diresibachew Haile Wondimu

  • Makinde Vincent Olubiyi

  • Onyinye Cynthia Okeke

  • Olufunke Onaadepo

  • Jimoh Abdulazeez

  • David Chibuike Ikwuka

  • Elemi John Ani

  • Abdullateef Isiaka Alagbonsi

  • July 14, 2026

Share

  • 1

    GLP-1 receptor agonists (GLP-1RAs) are associated with a significant reduction in overall cancer risk among type 2 diabetes mellitus (T2DM) patients.

  • 2

    Cancer-specific analyses revealed significant reductions in pancreatic, colorectal, endometrial, ovarian, hepatocellular, esophageal, and gastric cancers.

  • 3

    No significant associations were found between GLP-1RAs and thyroid, breast, kidney, or prostate cancers.

  • 4

    Mechanistic evidence regarding GLP-1RAs' influence on tumor biology is limited and primarily indirect.

  • 5

    The study highlights substantial heterogeneity and reliance on observational evidence, necessitating cautious interpretation of findings.

Original Source(s)

Cancer outcomes and biological mechanisms among patients with type 2 diabetes mellitus using glucagon-like peptide-1 receptor agonists: a systematic review and meta-analysis

  • by Ejike Daniel Eze, Leopold Ntakirutimana, Swase Dominic Terkimbi, Muluken Walle, Abdullahi Hussein Umar, Diresibachew Haile Wondimu, Makinde Vincent Olubiyi, Onyinye Cynthia Okeke, Olufunke Onaadepo, Jimoh Abdulazeez, David Chibuike Ikwuka, Elemi John Ani, Abdullateef Isiaka Alagbonsi

  • July 14, 2026

Related Content

Recombinant adenoviruses application for cancer vaccines: from genetic design to clinical translation

T cell-mediated immune function in gastric cancer: a bibliometric overview of the last 20 years (2006-2025)

A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer